# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rodman & Renshaw analyst Elemer Piros reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $14 price...
Chardan Capital analyst Daniil Gataulin initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rating and ann...
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rat...
B. Riley Securities analyst Mayank Mamtani reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $5 price...